Physician profile

Gregory Marra

Family Medicine · Hamburg, NY

NPI 1275997140

$11,792.34

in general payments reported to CMS, 2019-2025

54 companies · $3,147 in 2025

The $3,147 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,563.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,481.94 2021-2025 Airsupra, Farxiga, Breztri
Pfizer INC. $1,171.12 2019-2025
Lilly USA, LLC $1,165.73 2020-2025 Mounjaro, Jardiance, Zepbound
Novo Nordisk INC $1,126.67 2022-2025 Ozempic, Rybelsus, Wegovy
Abbvie INC. $896.22 2022-2025
Glaxosmithkline, LLC. $830.35 2020-2025 Trelegy Ellipta, Arexvy, Shingrix
Boehringer Ingelheim Pharmaceuticals, INC. $575.54 2022-2025 Jardiance, Spiriva Respimat, Stiolto Respimat
Amgen INC. $521.45 2020-2025 Repatha, Otezla, Repatha
Janssen Pharmaceuticals, INC $392.18 2020-2024 Xarelto
Exact Sciences Corporation $370.95 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Bayer Healthcare Pharmaceuticals INC. $340.51 2022-2025
Merck Sharp & Dohme LLC $216.56 2020-2025 Gardasil 9, Capvaxive, Gardasil
Dexcom, INC. $171.75 2022-2025 Dexcom G6 Transmitter
Phathom Pharmaceuticals, INC. $170.95 2024-2025 Voquezna
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $169.13 2025 Caplyta
Show all 54 companies
CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $135.34 2023-2025 Veozah
Novartis Pharmaceuticals Corporation $122.97 2022-2023
Corcept Therapeutics $120.58 2024-2025 Korlym
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $119.11 2025 Xifaxan
Sanofi-Aventis U.S. LLC $108.38 2019-2023
Otsuka America Pharmaceutical, INC. $106.28 2022-2024 Rexulti
Sumitomo Pharma America, INC. $102.36 2023-2025 Gemtesa
Biohaven Pharmaceutical Holding Company LTD. $101.29 2022
Idorsia Pharmaceuticals US INC $99.19 2023 Quviviq
Axsome Therapeutics, INC. $94.01 2025 Auvelity
E.R. Squibb & Sons, L.L.C. $87.50 2022-2024 Eliquis, Camzyos
Recor Medical INC $85.27 2025 Paradise Ultrasound Renal Denervation System
Abbott Laboratories $70.45 2024-2025 Freestyle Libre 3
Edwards Lifesciences Corporation $68.07 2024-2025 Sapien 3 Ultra Resilia
Pentax of America, INC. $66.03 2023-2025 Inspira, Pentax Medical, C2 Cryoballoon Focal Controller
Kowa Pharmaceuticals America, INC. $62.50 2022
Insulet Corporation $61.92 2025 Omnipod
Rayner Intraocular Lenses Limited $58.42 2025 Omidria
Shield Therapeutics INC $53.88 2023 Accrufer
Amneal Pharmaceuticals LLC $48.40 2024 Unithroid
Takeda Pharmaceuticals U.S.A., INC. $45.68 2022-2025 Trintellix
Eisai INC. $37.58 2021
Ferring Pharmaceuticals INC. $35.52 2025 Rebyota
Fujifilm Healthcare Americas Corporation $33.75 2023 Fujifilm
Oyster Point Pharma, INC. $22.53 2024 Tyrvaya
Boston Scientific Corporation $22.17 2025 Watchman Flx
Ardelyx, INC. $19.78 2024 Ibsrela
Amarin Pharma, INC. $19.62 2022
Rxsight INC $19.26 2023 Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge
Optinose US, INC. $19.07 2022
Vbi Vaccine (Delaware) INC. $18.03 2023 Prehevbrio
Genentech USA, INC. $17.83 2019
Lundbeck LLC $17.52 2022
Bausch & Lomb Americas INC. $17.50 2024 Vyzulta
Hikma Pharmaceuticals USA $16.82 2023 Ryaltris
Daiichi Sankyo INC. $15.65 2023 Injectafer
Ibsa Pharma INC. $14.30 2024 Licart, Tirosint
Biohaven Pharmaceuticals, INC. $13.68 2021
Travere Therapeutics, INC. $13.05 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gregory Marra

$11,792.34

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $3,147 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/7217367/gregory-marra

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.